Children's Oncology Group's 2013 blueprint for research: Renal tumors

Jeffrey S. Dome, Conrad V. Fernandez, Elizabeth A. Mullen, John A. Kalapurakal, James I. Geller, Vicki Huff, Eric J. Gratias, David B. Dix, Peter F. Ehrlich, Geetika Khanna, Marcio H. Malogolowkin, James R. Anderson, Arlene Naranjo, Elizabeth J. Perlman

Research output: Contribution to journalReview articlepeer-review

126 Scopus citations


Renal malignancies are among the most prevalent pediatric cancers. The most common is favorable histology Wilms tumor (FHWT), which has 5-year overall survival exceeding 90%. Other pediatric renal malignancies, including anaplastic Wilms tumor, clear cell sarcoma, malignant rhabdoid tumor, and renal cell carcinoma, have less favorable outcomes. Recent clinical trials have identified gain of chromosome 1q as a prognostic marker for FHWT. Upcoming studies will evaluate therapy adjustments based on this and other novel biomarkers. For high-risk renal tumors, new treatment regimens will incorporate biological therapies. A research blueprint, viewed from the perspective of the Children's Oncology Group, is presented.

Original languageEnglish
Pages (from-to)994-1000
Number of pages7
JournalPediatric Blood and Cancer
Issue number6
StatePublished - Jun 2013


  • Clear cell sarcoma
  • Malignant rhabdoid tumor
  • Renal cell carcinoma
  • Wilms tumor


Dive into the research topics of 'Children's Oncology Group's 2013 blueprint for research: Renal tumors'. Together they form a unique fingerprint.

Cite this